Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab

Authors: Gairing, Simon Johannes ¹, Mildenberger, Philipp ², Gile, Jennifer ³, Artusa, Fabian ⁴, Scheiner, Bernhard ⁵, Leyh, Catherine ⁶, Lieb, Sabine ⁷, Sinner, Friedrich ⁸, Jörg, Vincent ⁹, Fruendt, Thorben ⁹, Himmelsbach, Vera ¹⁰, Abedin, Nada ¹⁰, Sahin, Cennet ¹¹, Böttcher, Katrin ¹², Schuhbaur, Jasmin ¹³, Labuhn, Simon ¹⁴, Korolewicz, James ¹⁵, Fulgenzi, Claudia A.M. ¹⁵, D'Alessio, Antonio ¹⁵, Zanuso, Valentina ^{16, 17}, Hucke, Florian ¹⁸, Röhlen, Natascha ¹⁹, Ben Khaled, Najib ²⁰, Ramadori, Eleonora ²¹, Müller, Lukas ²², Weinmann, Arndt ¹, Kloeckner, Roman ²³, Galle, Peter Robert ¹, Tran, Nguyen H. ³, Venkatesh, Sudhakar K. ²⁴, Teufel, Andreas ^{25, 26}, Ebert, Matthias ^{26, 27}, De Toni, Enrico N. ²⁰, Waldschmidt, Dirk-Thomas ²¹, Marquardt, Jens U. ²⁸, Bettinger, Dominik ¹⁹, Peck-Radosavljevic, Markus ¹⁸, Geier, Andreas ²⁹, Reiter, Florian P. ²⁹, Rimassa, Lorenza ^{16, 17}, Pinato, David J. ^{15, 30}, Roderburg, Christoph ¹⁴, Ettrich, Thomas ¹³, Bitzer, Michael ³¹, Scheble, Veit ³¹, Ehmer, Ursula ¹², Berres, Marie-Luise ¹¹, Finkelmeier, Fabian ¹⁰, Gonzalez-Carmona, Maria Angeles ³², von Felden, Johann ⁹, Schulze, Kornelius ⁹, Venerito, Marino ⁸, van Bömmel, Florian ⁷, Jochheim, Leonie S. ⁶, Pinter, Matthias ⁵, Mohr, Raphael ⁴, Ilyas, Sumera I. ³³, Schmidtmann, Irene ², Foerster, Friedrich ^{1, ⁎}

Source: In JHEP Reports March 2025 7(3)

Ocrelizumab-induced colitis and cytomegalovirus infection and their disadvantageous interaction with underlying multiple sclerosis.

Authors: Lieb, Sabine, Heni, Maria, Rauschenberg, Sophie, Lange, Kay, Feisthammel, Juergen, Bläker, Hendrik, Wiegand, Johannes

Source: Zeitschrift für Gastroenterologie; Nov2023, Vol. 61 Issue 11, p1500-1503, 4p

SAT-501-YI The CRAFITY score to predict hepatocellular carcinoma disease control rate at month 12 in patients undergoing transarterial chemoembolization

Authors: Veelken, Rhea, Olbrich, Anne, Lieb, Sabine, Schindler, Aaron, Herber, Adam, Ebel, Sebastian, Denecke, Timm, Berg, Thomas, van Bommel, Florian

Source: In Journal of Hepatology June 2024 80 Supplement 1:S404-S404

OS-079-YI Development and validation of the CABLE score to estimate individual prognosis of patients with hepatocellular carcinoma treated with 1L atezolizumab and bevacizumab

Authors: Gairing, Simon Johannes, Mildenberger, Philipp, Gile, Jennifer, Artusa, Fabian, Scheiner, Bernhard, Leyh, Catherine, Lieb, Sabine, Sinner, Friedrich, Jörg, Vincent, Fruendt, Thorben, Himmelsbach, Vera, Abedin, Nada, Sahin, Cennet, Boettcher, Katrin, Schuhbaur, Jasmin, Labuhn, Simon, Korolewicz, James, Fulgenzi, Claudia, D'Alessio, Antonio, Zanuso, Valentina, Hucke, Florian, Röhlen, Natascha, Khaled, Najib Ben, Ramadori, Eleonora, Müller, Lukas, Weinmann, Arndt, Kloeckner, Roman, Galle, Peter R., Tran, Nguyen H., Venkatesh, Sudhakar, Teufel, Andreas, de Toni, Enrico, Waldschmidt, Dirk-Thomas, Marquardt, Jens U., Bettinger, Dominik, Peck-Radosavljevic, Markus, Geier, Andreas, Reiter, Florian P, Rimassa, Lorenza, Pinato, David J., Roderburg, Christoph, Ettrich, Thomas, Bitzer, Michael, Scheble, Veit, Ehmer, Ursula, Berres, Marie-Luise, Finkelmeier, Fabian, Gonzalez-Carmona, Maria Angeles, von Felden, Johann, Schulze, Kornelius, Venerito, Marino, van Bömmel, Florian, Jochheim, Leonie, Pinter, Matthias, Mohr, Raphael, Ilyas, Sumera I., Schmidtmann, Irene, Foerster, Friedrich

Source: In Journal of Hepatology June 2024 80 Supplement 1:S52-S52

Atezolizumab Plus Bevacizumab in Patients with Advanced and Progressing Hepatocellular Carcinoma: Retrospective Multicenter Experience.

Authors: Sinner, Friedrich, Pinter, Matthias, Scheiner, Bernhard, Ettrich, Thomas Jens, Sturm, Niklas, Gonzalez-Carmona, Maria A., Waidmann, Oliver, Finkelmeier, Fabian, Himmelsbach, Vera, De Toni, Enrico N., Ben Khaled, Najib, Mohr, Raphael, Fründt, Thorben Wilhelm, Kütting, Fabian, Bömmel, Florian van, Lieb, Sabine, Krug, Sebastian, Bettinger, Dominik, Schultheiß, Michael, Jochheim, Leonie S.

Source: Cancers; Dec2022, Vol. 14 Issue 23, p5966, 12p

Subject Terms: THERAPEUTIC use of monoclonal antibodies, DRUG efficacy, MIDDLE age, RESEARCH, CONFIDENCE intervals, IMMUNE checkpoint inhibitors, RETROSPECTIVE studies, TREATMENT effectiveness, BEVACIZUMAB, PROGRESSION-free survival, ADVERSE health care events, HEPATOCELLULAR carcinoma, OLDER people, IMMUNOTHERAPY, EVALUATION

Geographic Terms: GERMANY, AUSTRALIA

FRI-299 - CRAFITY score is associated with overall survival in patients with hepatocellular carcinoma treated with transarterial chemoembolisation

Authors: Veelken, Rhea, Olbrich, Anne, Schindler, Aaron, Lieb, Sabine, Fischer, Janett, Ebel, Sebastian, Denecke, Timm, Berg, Thomas, van Bömmel, Florian

Source: In Journal of Hepatology June 2023 78 Supplement 1:S507-S507

THU586 - Interleukin 10 and Interferon Gamma levels are elevated in patients with hepatocellular carcinoma showing response to treatment with atezolizumab and bevacizumab

Authors: Lieb, Sabine, Schindler, Aaron, Niemeyer, Johannes, Veelken, Rhea, Fischer, Janett, Al-Sayegh, Rami, Berg, Thomas, van Bömmel, Florian

Source: In Journal of Hepatology July 2022 77 Supplement 1:S382-S382